Imvacs
Imvacs

Cambridge Healthtech Institute’s Eleventh Annual
Advances in Vaccine Technologies
Part of the Eleventh Annual ImVacS: Immunization and Vaccine Summit
December 7-8, 2016 | Revere Hotel | Boston, MA


Vaccine technology has evolved significantly in the last decade, profoundly changing the future of vaccine development. The urgent need to accelerate response time to emerging threats, make vaccines more widely available and ready for quick deployment, develop vaccines against difficult targets, and improve delivery systems for maximum potency have been the impetus behind many advances in vaccine technology. Synthetic vaccine candidates, genomic analysis of disease progression and vaccine response, structure-based antigen design, and nanoparticle delivery systems are just a few of the realizations of this effort. CHI’s Eleventh Annual Advances in Vaccine Technologies will present the latest advancements and applications of vaccine technology, and a look forward to overcoming current challenges.

Final Agenda

Day 1 | Day 2 | Download Brochure

Wednesday, December 7

7:15 am Registration Open and Morning Coffee

 


Advancing Vaccines for Infectious Diseases and Emerging Threats

8:10 Chairperson’s Opening Remarks

Harry Kleanthous, Ph.D., Associate Vice President, Head, Research (North America), Sanofi Pasteur

8:15 Novel Antigen Design and Functional Immune Assessments

Nicholas Jackson, Ph.D., Vice President, Head of Research, Sanofi Pasteur

8:45 Advances in DNA Vaccines for Infectious Diseases

Laurent M. Humeau, Ph.D., Vice President, Research & Development, Inovio Pharmaceuticals

Inovio is revolutionizing vaccines to prevent and treat today’s cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile.

9:15 Technologies for Malaria Vaccine Development

Annie Mo, Ph.D., Program Officer, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Malaria is a devastating disease that affects hundreds of millions of people around the world. Vaccine development becomes critical for the prevention of and the ultimate elimination of malaria and to combat any potential drug resistant parasites. Although the first generation of malaria vaccine RTS,S/AS01 with moderate vaccine efficacy of around 30-40% in children with a 3-dose regimen by 48 months post immunization is on its way to licensure, development of a second generation of vaccine with an improved and prolonged efficacy became imperative. Current advances in malaria vaccine R&D and applicable new technologies to address malaria vaccinology and immunology issues will be presented.

9:45 Use of Systems Serology to Define How Genetic Adjuvants Modify an Antibody Response Generated by a DNA Prime/Subunit Boost Protocol

Kenneth Bagley, Ph.D., Head, Adjuvant Discovery & Development, Profectus BioSciences

Genetic-based adjuvants can enhance an immune response to a DNA vaccine quite dramatically. We utilized systems serology to understand how different genetic adjuvants can modify an antibody response to protect or not against a heterologous SIV challenge. Exploiting multivariate analysis, we are able to predict which animals received which adjuvant. This approach can be used to potentially predict immune regimens that could be protective in clinical trials.

10:15 Mechanism of Live Attenuated L. interrogans FcpA Vaccine in a Murine Model of Infection

Haritha Adhikarla, Ph.D., Associate Research Scientist, Albert Ko Laboratory, Yale School of Public Health 

10:30 Coffee Break in the Exhibit Hall with Poster Viewing


Virus-Like Particle and Nanoparticle Vaccines

11:00 Phase 1 Clinical Trial Investigation of Synthetic Vaccine Particles (SVP) to Prevent Anti-Drug Antibodies Against a Pegylated Uricase in Subjects with Hyperuricemia

Takashi K. Kishimoto, Ph.D., CSO, Selecta Biosciences

We have created tolerogenic vaccines using synthetic, self-assembling, biodegradable poly(lactide-co-glycolide) (PLGA) nanoparticles containing rapamycin to induce antigen-specific immune tolerance. Co-administration of these synthetic vaccine particles (SVP) with biologic drugs mitigates the formation of anti-drug antibodies, a common cause for treatment failure and adverse events associated with biologic therapies. SEL-212, our SVP combined with pegylated uricase, is currently being evaluated in Phase I clinical trials in patients with hyperuricemia.

11:30 Enveloped Virus-Like Particles

David Anderson, Ph.D., CSO, VBI Vaccines, Inc.

In the past decade, virus-like particles have emerged as a powerful method for antigen presentation and a tremendous commercial success. VBI Vaccines, Inc. has created a next-generation antigen virus like particle capable of expressing envelope proteins within a lipid membrane – a true natural mimic for enveloped viruses. VBI will present data demonstrating the unique properties of this platform, including potency and commercial relevance of the platform by case study of its Phase I CMV vaccine candidate.

12:00 pm Advancements in Cell Culture-Produced Influenza Vaccines

Amine Kamen, Ph.D., Professor, Bioengineering, McGill University

Over the last decade, public health authorities invested massively to support the development of rapid responses to influenza pandemic threats. Two cell culture-based novel influenza vaccines have been approved. Other advanced vaccination approaches rely on virus-like particle (VLP) strategies. Progresses in influenza vaccine cell-culture manufacturing technologies will be presented and discussed. Influenza VLP produced in insect cells by baculovirus infection and HEK-293 cells by plasmid transfection will be compared from a process standpoint.

12:30 Enjoy Lunch on Your Own


Vaccine Delivery Technologies

2:10 Chairperson’s Remarks

Ali Fattom, Ph.D., Senior Vice President, Vaccine R&D, NanoBio

2:15 NanoStatTM Technology Enables Intranasal Vaccine to Induce Immunity against Infection by and Transmission of Respiratory and Sexually Transmitted Viral or Bacterial Pathogens

Ali Fattom, Ph.D., Senior Vice President, Vaccine R&D, NanoBio

Two major reasons why the field of mucosal immunity is lagging behind are: i) lack of suitable delivery and adjuvants, and ii) difficulty in defining surrogate markers for protection. NanoStatTM technology, a unique nanoemulsion (NE) was shown to efficiently deliver vaccines intranasally (IN), and trigger a balanced systemic and mucosal immunity. Our data with HSV2, pertussis, and flu demonstrate this technology is well-suited for developing vaccines to protect against disease, prevent carriage, and eliminate transmission.

Precision Nano Systems2:45 A Microfluidics Platform for the Seamless Development of Lipid- and Polymer-based Nanoparticle Vaccines

Euan Ramsay, Ph.D., Co-Founder & COO, Leadership, Precision NanoSystems, Inc.

Nanoparticulate delivery systems such as lipid nanoparticles, liposomes and polymer-based nanoparticles have been widely used to develop vaccines. However, realizing the potential of nanoparticle vaccines has been hindered by challenges reproducibly manufacturing these systems at the desired scale. This presentation will describe the NanoAssemblr™ platform, a suite of microfluidics-based instruments for the manufacture of nanoparticles from discovery to clinical scale. Examples of lipid- and polymer-based nanoparticle systems manufactured with the NanoAssemblr platform will be described. The modularity of the manufacturing platform and its potential for customization to meet both the needs of large-scale production and small-scale personalized cancer vaccines will also be explored.

3:15 Can Skin Vaccination Eliminate MNT in Developing Countries?

Ioanna Skountzou, M.D., Ph.D., Associate Professor, Microbiology and Immunology, Emory University School of Medicine

3:45 Refreshment Break in the Exhibit Hall with Poster Viewing

4:15 Vaccine Delivery and Packaging Technologies for Low Resource Settings

Annie Rein-Weston, MPH, Technical Coordinator, Vaccine and Pharmaceutical Technologie, PATH

This presentation will include an overview of program requirements for vaccine delivery in low-resource settings as well as examples of current challenges that are faced in low- and middle-income countries (LMICs). Examples of active research that are occurring in the development and use of alternative delivery and packaging technologies in LMICs will also be discussed.

4:45 Panel Discussion with the Speakers: The Future of Vaccine Technologies

Moderator: Simon Delagrave, Ph.D., Senior Director, Head of Virology Research North America, Sanofi Pasteur

Panelists:

David Anderson, Ph.D., CSO, VBI Vaccines

Ali Fattom, Ph.D., Senior Vice President, Vaccine R&D, NanoBio

Kenneth Bagley, Ph.D., Head, Adjuvant Discovery & Development, Profectus BioSciences

Amine Kamen, Ph.D., Professor, Bioengineering, McGill University

  • What innovative technologies will keep us ahead of emerging threats?
  • What is the role of nanoparticle and VLP technology in next-generation vaccines?
  • How will new vaccine delivery technologies improve overall response?

Avanti Polar Lipids5:45-6:45 Welcome Reception in the Exhibit Hall with Poster Viewing

 

Day 1 | Day 2 | Download Brochure

Thursday, December 8

7:15 am Morning Coffee


Universal Influenza Vaccine Design

8:30 Chairperson’s Remarks

Nikolai Petrovsky, MBBS, Ph.D., Chairman & Research Director, Vaxine; Professor, Flinders University

8:35 Novel Vaccines that Elicit Broadly Protective Immune Responses against Influenza

Simon Delagrave, Ph.D., Senior Director, Head of Virology Research North America, Sanofi Pasteur

Annual vaccination against seasonal influenza A and B virus subtypes with a well-matched inactivated virus vaccine is highly effective against influenza infection and disease. However, selective immune pressure on viral hemagglutinin (HA) results in antigenic drift of influenza strains. The development of a broadly protective influenza vaccine that can protect against matched and drifted mismatched strains through induction of broadly cross-protective functional antibody responses would provide significant improvement over the current standard of care. This presentation will show how Sanofi Pasteur is studying antibodies elicited by commercial vaccine to understand broadly cross-protective antibodies and, using Computationally Optimized Broadly Reactive Antigens (COBRAs), working to develop novel vaccines that elicit broadly protective immune responses against influenza. Studies funded by Sanofi Pasteur.

9:05 Design of a Universal Influenza Vaccine

Nikolai Petrovsky, MBBS, Ph.D., Chairman & Research Director, Vaxine; Professor, Flinders University

Highly adaptable viruses including influenza continue to circumvent attempts to control them using traditional vaccine approaches. To overcome such challenges and design a universal influenza vaccine, better understanding is needed of viral antigenic structures and their evolution along with better understanding of protective adaptive immunity. Computer structural models identify features that can then be incorporated into synthetic antigens to build a universal influenza vaccine. High-throughput in silico screening approaches identify immune-modulators for fine-tuning of the vaccine response. These tools enable design of vaccines that induce broadly cross-neutralizing and long-lasting B and T cell responses. This heralds an era of intelligent vaccine design, allowing accelerated design of vaccines against rapidly evolving viral targets.

9:35 Development of Universal Influenza Vaccine Targeting Conserved Domains

Yawei Ni, Ph.D., President & CSO, KJ Biosciences

Targeting conserved domains for cross protection is essential to development of a universal influenza vaccine. We are developing two complimentary approaches toward this goal. One is novel antigen constructs with a self-assembling nanoparticle carrier which allows combination of conserved domains for enhanced protection. The other is low-pH treatment under proper conditions of influenza antigens to enhance immune responses against conserved domains, which could improve current inactivated vaccines for broader protection.

10:05 Coffee Break in the Exhibit Hall with Poster Viewing


Translating Technology to Trials

10:35 Cytomegalovirus Vaccine V160: Translating Experimental Findings to Clinical Trials

Dai Wang, Ph.D., Senior Scientist, Merck

Cytomegalovirus (CMV) causes significant morbidity and mortality in neonates and severely immunocompromised individuals. To address the unmet medical need, we have developed a conditionally replication defective vaccine, termed V160. The candidate is currently under clinical evaluation. This presentation will discuss the scientific premise, preclinical properties and latest progress of V160.

11:05 Late Breaking Presentation

 

11:35 Close of Conference



Day 1 | Day 2 | Download Brochure

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


2016 ImVacS-Immunization and Vaccine Summit

Download Brochure



2017 Final Agenda

Corporate Sponsors

Avanti Polar Lipids

 

Precision Nano Systems

Corporate Support Sponsor

ShahinGharakhanianConsulting

View All Sponsors

View Media Partners



Re-Entering Antibacterial Discovery and Development Summit